Figure 6.

Survival curves for three cohorts of mice with orthotopic tumors generated by LLC, CmKPP.1 or SmKPP.1, comparing treatment with immunotherapy to control (1XPBS). Within each cohort, mice underwent weekly intraperitoneal injections of immunotherapy with anti-PD-1 on Tuesdays and anti-PD-L1 on Thursdays; control mice were injected with 1× PBS on the same days. (A) Survival of three control cohorts demonstrates that LLC is more aggressive than CmKPP.1 and SmKPP.1; and CmKPP.1 is more aggressive than SmKPP.1. (B) Survival of LLC cohort comparing immunotherapy to PBS is consistent with other data that orthotopic tumors generated by LLC most likely has primary resistance to immunotherapy. (C) CmKPP.1 cohort and (D) SmKPP.1 cohort demonstrate orthotopic tumors are initially responsive to immunotherapy when compared to PBS, but are lethal, suggesting mice develop secondary resistance.